Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study

Alessandro Martorana; C. Motta; G. Koch; M. Massaia; S. Mondino; I. Raniero; A. Vacca; F. Di Lorenzo; G. Cavallo; E. Oddenino; E. Pavanelli; M. Maniscalco; V. Montano; A. Mastropietro; N. C. Bellia; E. Ciravegna; M. La Rocca; E. Vitale; F. Lorico; B. Zacchettin; A. Scalise; A. Codemo; C. Gabelli; M. Spano; S. Poli; D. Panuccio; P. Bruno; P. Alfieri; R. Ruggiero; F. Cursi; G. Levi della Vida

Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study

Alessandro Martorana, C. Motta, G. Koch, M. Massaia, S. Mondino, I. Raniero, A. Vacca, F. Di Lorenzo, G. Cavallo, E. Oddenino, E. Pavanelli, M. Maniscalco, V. Montano, A. Mastropietro, N. C. Bellia, E. Ciravegna, M. La Rocca, E. Vitale, F. Lorico, B. ZacchettinA. Scalise, A. Codemo, C. Gabelli, M. Spano, S. Poli, D. Panuccio, P. Bruno, P. Alfieri, R. Ruggiero, F. Cursi, G. Levi della Vida

Research output: Contribution to journal › Article › peer-review

Abstract

Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient’s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.

Original language	English
Pages (from-to)	15-20
Number of pages	6
Journal	Journal of Gerontology and Geriatrics
Volume	66
Issue number	1
Publication status	Published - Jan 1 2018

Keywords

Alzheimer’s disease
Homotaurine
Mild cognitive impairment

ASJC Scopus subject areas

Ageing
Geriatrics and Gerontology

Cite this

Martorana, A., Motta, C., Koch, G., Massaia, M., Mondino, S., Raniero, I., Vacca, A., Di Lorenzo, F., Cavallo, G., Oddenino, E., Pavanelli, E., Maniscalco, M., Montano, V., Mastropietro, A., Bellia, N. C., Ciravegna, E., La Rocca, M., Vitale, E., Lorico, F., ... Levi della Vida, G. (2018). Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study. Journal of Gerontology and Geriatrics, 66(1), 15-20.

Martorana, A, Motta, C , Koch, G, Massaia, M, Mondino, S, Raniero, I, Vacca, A, Di Lorenzo, F, Cavallo, G, Oddenino, E, Pavanelli, E, Maniscalco, M, Montano, V, Mastropietro, A, Bellia, NC, Ciravegna, E, La Rocca, M, Vitale, E, Lorico, F, Zacchettin, B, Scalise, A, Codemo, A, Gabelli, C, Spano, M, Poli, S, Panuccio, D, Bruno, P, Alfieri, P, Ruggiero, R, Cursi, F & Levi della Vida, G 2018, 'Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study', Journal of Gerontology and Geriatrics, vol. 66, no. 1, pp. 15-20.

@article{67d9e466e1764f03905186b5573dba88,

title = "Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study",

abstract = "Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient{\textquoteright}s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.",

keywords = "Alzheimer{\textquoteright}s disease, Homotaurine, Mild cognitive impairment",

author = "Alessandro Martorana and C. Motta and G. Koch and M. Massaia and S. Mondino and I. Raniero and A. Vacca and {Di Lorenzo}, F. and G. Cavallo and E. Oddenino and E. Pavanelli and M. Maniscalco and V. Montano and A. Mastropietro and Bellia, {N. C.} and E. Ciravegna and {La Rocca}, M. and E. Vitale and F. Lorico and B. Zacchettin and A. Scalise and A. Codemo and C. Gabelli and M. Spano and S. Poli and D. Panuccio and P. Bruno and P. Alfieri and R. Ruggiero and F. Cursi and {Levi della Vida}, G.",

year = "2018",

month = jan,

day = "1",

language = "English",

volume = "66",

pages = "15--20",

journal = "Journal of Gerontology and Geriatrics",

issn = "2499-6564",

publisher = "Pacini Editore s.r.l.",

number = "1",

}

TY - JOUR

T1 - Effect of homotaurine in patients with cognitive impairment

T2 - Results from an Italian observational retrospective study

AU - Martorana, Alessandro

AU - Motta, C.

AU - Koch, G.

AU - Massaia, M.

AU - Mondino, S.

AU - Raniero, I.

AU - Vacca, A.

AU - Di Lorenzo, F.

AU - Cavallo, G.

AU - Oddenino, E.

AU - Pavanelli, E.

AU - Maniscalco, M.

AU - Montano, V.

AU - Mastropietro, A.

AU - Bellia, N. C.

AU - Ciravegna, E.

AU - La Rocca, M.

AU - Vitale, E.

AU - Lorico, F.

AU - Zacchettin, B.

AU - Scalise, A.

AU - Codemo, A.

AU - Gabelli, C.

AU - Spano, M.

AU - Poli, S.

AU - Panuccio, D.

AU - Bruno, P.

AU - Alfieri, P.

AU - Ruggiero, R.

AU - Cursi, F.

AU - Levi della Vida, G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient’s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.

AB - Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient’s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.

KW - Alzheimer’s disease

KW - Homotaurine

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=85044960365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044960365&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85044960365

SN - 2499-6564

VL - 66

SP - 15

EP - 20

JO - Journal of Gerontology and Geriatrics

JF - Journal of Gerontology and Geriatrics

IS - 1

ER -

Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this